Significance of myocardial injury on in-hospital clinical outcomes of in-hospital and COVID-19 patients

Vyas, Pooja; Mishra, Ashish; Parwani, Kunal; Patel, Iva; Dhokia, Dhara; Amin, Trishul; Shah, Prarthi; Boob, Tanmay; Parikh, Rujuta; Dake, Radhakishan; Banker, Khamir

doi:10.34172/jcvtr.2023.31614

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering its importance in cardiovascular disease, a population-based study showed that higher ACE2 plasma levels are associated with a greater risk of severe cardiovascular disease [20]. COVID-19 has been found to increase the risk of cardiogenic shock [21,22], cardiac arrhythmias [23,24], acute myocardial injury [25,26] and sometimes sudden death in patients with cardiovascular disease [15,27,28], and at the same time, patients with cardiovascular disease have a higher risk of mortality due to COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Cardiovascular Comorbidities in COVID-19: Comprehensive Analysis of Key Topics

Markovič,

Ternar,

Trstenjak

et al. 2024

Interact J Med Res

View full text Add to dashboard Cite

Background:The interrelation between COVID-19 and various cardiovascular and metabolic disorders has been a critical area of study. There is a growing need to understand how comorbidities like cardiovascular diseases and metabolic disorders affect the risk and severity of COVID-19. Objective:The objective of this study is to systematically analyze the association between COVID-19 and cardiovascular and metabolic disorders. The focus is on comorbidity, examining the role of cardiovascular diseases such as embolism, thrombosis, hypertension, and heart failure, as well as metabolic disorders like glucose and iron metabolism disorders. Methods:Our study involved a systematic search in PubMed for literature published from 2000 to 2022. We established two databases: one for COVID-19-related articles and another for CVD-related articles, ensuring all were peer-reviewed. In terms of data analysis, statistical methods were applied to compare the frequency and relevance of MeSH terms between the two databases. This involved analyzing the differences and ratios in the usage of these terms and employing statistical tests to determine their significance in relation to key CVDs within the COVID-19 research context. Results:The study revealed that "cardiovascular diseases" and "nutritional and metabolic diseases" were highly relevant LV1 MeSH descriptors in COVID-19 comorbidity research. Detailed analysis at LV2 and LV3 levels showed "vascular disease" and "heart disease" as prominent descriptors under cardiovascular diseases. Significantly, "glucose metabolism disorders" were frequently associated with COVID-19 comorbidities such as embolism, thrombosis, and heart failure. Furthermore, iron deficiency (ID) was notably different in its occurrence between COVID-19 and CVD articles, underlining its significance in the context of COVID-19 comorbidities. Statistical analysis underscored these differences, highlighting the importance of both glucose and iron metabolism disorders in COVID-19 research.Conclusions: This work lays the foundation for future research using a knowledge-based approach to elucidate the intricate relationships between these conditions, with the aim of developing more effective healthcare strategies and interventions in the face of ongoing pandemic challenges.

show abstract

Section: Introductionmentioning

confidence: 99%

Cardiovascular Comorbidities in COVID-19: Comprehensive Analysis of Key Topics

Markovič,

Ternar,

Trstenjak

et al. 2024

Interact J Med Res

View full text Add to dashboard Cite

show abstract

Cardiac troponin in hospitalized COVID-19 patients: Incidence, predictors, and outcomes

Gupta,

Bansal

et al. 2023

Ann Clin Biochem

View full text Add to dashboard Cite

Background The incidence, predictors, and association of cardiac troponin with mortality in hospitalized COVID-19 were not adequately studied in the past and were also not reported from an Indian hospital. Methods In this retrospective cohort study, the cardiac troponin of 240 hospitalized COVID-19 patients was measured. The incidence, predictors, and association of elevated cardiac troponin with in-hospital mortality were determined among hospitalized COVID-19 patients. Results The cardiac troponin was elevated in 12.9% (31/240) of the patients. The troponin was elevated in the patients in the older age group (64 years vs. 55 years, p = .002), severe COVID-19 illness (SpO2 < 90%) (93.5% vs. 60.8%, p < .001), low arterial oxygen saturation (SpO2) (80% vs. 88%, p = .001), and low PaO2/FiO2 ratio ( p < .0001). The patients with elevated cardiac troponin had elevated total leukocyte counts (TLC) ( p = .001), liver enzyme ( p = .025), serum creatinine ( p = .011), N-terminal-Pro Brain natriuretic peptide ( p < .0001), and d-dimer ( p < .0001). The majority of the patients with elevated cardiac troponin were admitted to the intensive care unit (90.3% vs. 51.2%; p < .0001), were on a ventilator (61.3% vs. 21.5%; p < .0001), and had higher mortality (64.5% vs. 19.6%; p < .0001). The Kaplan–Meir survival analysis showed that the patients with elevated troponin had worse survival ( p log-rank<.0001). Age, NT-ProBNP, d-dimer, and ventilator were the predictors of elevated troponin in multivariate logistic regression analysis. The Cox-regression analysis showed a significant association between elevated cardiac troponin and in-hospital mortality (adjusted hazard ratio 2.13; 95% confidence interval [CI] 1.145–3.97; p = .017). Two-thirds (65%) of patients with elevated cardiac troponin died during their hospital stay. Conclusions COVID-19 patients with elevated cardiac troponin had severe COVID illness, were more commonly admitted to an intensive care unit, were on a ventilator, and had high in-hospital mortality.

show abstract

Significance of myocardial injury on in-hospital clinical outcomes of in-hospital and COVID-19 patients

Cited by 2 publications

References 9 publications

Cardiovascular Comorbidities in COVID-19: Comprehensive Analysis of Key Topics

Cardiovascular Comorbidities in COVID-19: Comprehensive Analysis of Key Topics

Cardiac troponin in hospitalized COVID-19 patients: Incidence, predictors, and outcomes

Contact Info

Product

Resources

About